Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.63 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3911707 | 0.84 | CA2 (0.68) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL18541163 | 0.82 | USP2 (0.66) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL5491789 | 0.82 | USP2 (0.71) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL8458547 | 0.81 | USP2 (0.60) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL8454582 | 0.81 | USP2 (0.60) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL11692574 | 0.81 | USP2 (0.69) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL22414705 | 0.81 | USP2 (0.69) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL5323183 | 0.80 | CA2 (0.68) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL8460512 | 0.79 | CA2 (0.73) | CA2CA1USP2MAPK1TSHR | |
| SCHEMBL23808369 | 0.79 | CA2 (0.61) | CA2CA1USP2MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378551-B2 | Amide compound | KAO CORPORATION (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20070185208-A1 | Amide compound | KAO CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185208-A1 | Amide compound | H1-0, H1-2, H1-4 | CA2 4332/4885CA1 4192/4885USP2 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.